IFNG and neoplasm: Although identification of baseline gene signatures predictive of response has gained some traction (e.g., tumor mutational burden or interferon gamma gene signatures), there are few publications that attempt to identify markers (biologic, radiologic, or otherwise) that correlate with OS and can be measured at early timepoints after the onset of ICB therapy.